Antibodies directed to the deletion mutants of epidermal...

Details Antibodies directed to the deletion mutants of epidermal... Antibodies directed to the deletion mutants of epidermal...

2004-06-25

2010-06-15

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S142100, C424S143100, C424S178100, C424S181100, C424S183100, C435S070210, C435S810000, C530S387100, C530S388100, C530S388150, C530S388220, C530S391700

Reexamination Certificate

active

07736644

ABSTRACT:
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3896111 (1975-07-01), Kupchan et al.
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4681581 (1987-07-01), Coates
patent: 4735210 (1988-04-01), Goldenberg
patent: 5101827 (1992-04-01), Goldenberg
patent: 5102990 (1992-04-01), Rhodes
patent: 5194594 (1993-03-01), Khawli et al.
patent: 5212290 (1993-05-01), Vogelstein et al.
patent: 5401828 (1995-03-01), Vogelstein et al.
patent: 5576288 (1996-11-01), Lappi et al.
patent: 5627052 (1997-05-01), Schrader
patent: 5648471 (1997-07-01), Buttram et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5710010 (1998-01-01), Vogelstein et al.
patent: 5814317 (1998-09-01), Vogelstein et al.
patent: 5939598 (1999-08-01), Kucherlapati
patent: 5981725 (1999-11-01), Vogelstein et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6127126 (2000-10-01), Vogelstein et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6224868 (2001-05-01), Wong et al.
patent: 6235883 (2001-05-01), Jakobovits et al.
patent: 6342219 (2002-01-01), Thorpe
patent: 6441163 (2002-08-01), Chari et al.
patent: 6455498 (2002-09-01), Vogelstein et al.
patent: 6673986 (2004-01-01), Kucherlapati et al.
patent: 7084257 (2006-08-01), Deshpande et al.
patent: 639726 (1991-04-01), None
patent: 2066428 (1990-08-01), None
patent: 69025946 (1996-04-01), None
patent: 58481 (1982-08-01), None
patent: 88046 (1983-09-01), None
patent: 102324 (1984-03-01), None
patent: 142641 (1985-09-01), None
patent: 143949 (1988-10-01), None
patent: 36676 (1990-09-01), None
patent: 491007 (1992-06-01), None
patent: 0 463 151 (1996-06-01), None
patent: 607934 (1985-01-01), None
patent: 3 068 180 (1991-03-01), None
patent: 3 068 506 (1991-03-01), None
patent: 3 068 507 (1991-03-01), None
patent: 2975679 (1999-11-01), None
patent: WO 91/03489 (1991-03-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 9616988 (1996-06-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 00/76310 (2000-12-01), None
patent: WO 01/00244 (2001-01-01), None
patent: WO 01/62931 (2001-08-01), None
patent: WO 03/047336 (2003-06-01), None
Janway et al, p. 3:1-3:3, in Immunobiology, 1994.
Kobrin et al, J Immunology 146: 2017-2020, 1991.
Barrios et al, J Molecular Recognition 17: 332-338, 2004.
Mendelsohn, Cancer Cells 7:359 (1989).
Mendelsohn, “Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents”, J Steroid Biochem Mol Biol, Dec. 20, 1990; 37 (6):889-92.
Mendelsohn, The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies, Semin Cancer Biol, Oct. 1990; 1(5):339-44.
U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.
U.S. Appl. No. 07/531,410, filed Jun. 1, 1990, Vogelstein.
Schmidt et al., Expression of an Oncogenic Mutant EGF Receptor Markedly Increases The Sensitivity of Cells to an EGF-Receptor-Specific Antibody-Toxin,Int. J. Cancer, 75, 878-884 (Mar. 16, 1998).
U.S. Appl. No. 07/466,008, filed Jan. 12, 1990, Kucherlapati.
U.S. Appl. No. 07/610,515, filed Nov. 8, 1990, Kucherlapati, et al.
U.S. Appl. No. 07/919,297, filed Jul. 30, 1992, Kucherlapati et al.
U.S. Appl. No. 08/112,848, filed Aug. 27, 1993, Kucherlapati.
U.S. Appl. No. 08/234,145, filed Apr. 28, 1994, Kucherlapati et al.
U.S. Appl. No. 08/376,279, filed Jan. 20, 1995, Jakobovitz et al.
U.S. Appl. No. 08/430,938, filed Apr. 27, 1995, Kucherlapati et al.
U.S. Appl. No. 08/462,837, filed Jun. 5, 1995, Kucherlapati et al.
U.S. Appl. No. 08/463,191, filed Jun. 5, 1995, Kucherlapati et al.
U.S. Appl. No. 08/464,584, filed Jun. 5, 1995, Jakobovitz et al.
U.S. Appl. No. 08/486,853, filed Jun. 5, 1995, Kucherlapati et al.
U.S. Appl. No. 08/486,859, filed Jun. 5, 1995, Kucherlapati et al.
U.S. Appl. No. 08/759,620, filed Dec. 3, 1996, Jakobovits et al.
Babcook et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A.93(15):7843-8 (1996).
Batra et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6(10):1251-9 (1995).
Bigner et al., (1988) J. Neuropathol. Exp. Neurol., 47:191-205.
Burnol et al, in Antibody Mediated Delivery Systems 55-79 (J. Rodwell, ed. 1988).
Chothia, et al. (Nature. Dec. 21-28, 1989;342(6252):877-83).
Deo et al. Immunology Today (1997) 18:127.
Diener et al, in Antibody Mediated Delivery Systems 1-23 (J. Rodwell, ed. 1988).
Dillman et al. Superiority of an Acid-labile Daunorubicin-Monoclonal antibody Immunoconjugate compared to free drug. Cancer Res. (1988) 48:6097-6102.
Dillman et al. Preclinical trials with conbinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res. (1986) 46:4886-4891.
Doronina et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology. (2003) 21: 778-784.
Downward et al. Close Similarity of Epidermal Growth Factor Receptor and v-erbB Oncogene Protein Sequence. Nature (1984) 307:521-527.
Dubowchik et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. (1998) 8(23):3347-52.
Endo et al. Cancer Res. (1980) 47:1076-1080.
Francisco et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003 [Epub ahead of print]. Epub Apr. 24, 2003.
Fung et al., (1984) Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus. Cell 33:357-368.
Gammett et al., (1986). Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes. Proc. Natl. Acad. Sci. USA 83:6053-6057).
Garcia de Palazzo, IE. et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. 53(14):3217-20 (1993).
Garnett et al. Cancer Res. 46:2407-2412 (1986).
Ge H. et al. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 98(3):357-61 (2002).
Ghose et al, in Targeted Drugs 1-22 (E. Goldberg, ed. 1983).
Gilmore et al., (1985). Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro. Cell 40:609-618.
Green and JakobovitsJ. Exp. Med. 188:483-495 (1998).
Humphrey et al., (1988). Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts. Cancer Research 48:2231-2238.
Hurwitz et al. Appl. Biochem. 2:25-35 (1980).
Jungbluth et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 100(2):639-44 (2003).
Junghans et al. inCancer Chemotherapy and Biotherapy655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996).
Kato et al. J. Med. Chem. 27:1602-1607 (1984).
Kris et al., (1985). Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein. Cell 40:619-625.
Kuan et al. EGF mutant receptor vIII as a mole

Affiliated with

Also associated with

Rating

Antibodies directed to the deletion mutants of epidermal... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies directed to the deletion mutants of epidermal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies directed to the deletion mutants of epidermal... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4227712